Does Ki-67 Have a Role in the Diagnosis of Placental Molar Disease?

Int J Gynecol Pathol. 2020 Jan;39(1):1-7. doi: 10.1097/PGP.0000000000000558.

Abstract

The use of p57 immunohistochemistry (IHC) can distinguish complete mole (CM) from partial mole (PM) and nonmolar abortus (NMA). Molecular genotyping (MG) is the gold standard method for the definitive diagnosis of PM and NMA. However, MG is expensive and not always available. Some data suggest Ki-67 IHC may be helpful in distinguishing NMAs from PMs and could be a substitute for MG. In this study, we examined the utility of p57 and Ki-67 IHC stains in the diagnosis of placental molar disease. The study cohort consisted of 60 cases of products of conception (20 CMs, 20 PMs, and 20 NMAs). All CM cases showed absent (<10%) p57 IHC in chorionic villi. All PM and NMA cases had been subjected to MG and showed diandric triploid or biparental inheritance, respectively. Ki-67 and p57 IHC staining was done on formalin-fixed paraffin-embedded sections from all 60 cases. Both IHC stains were interpreted blinded to the diagnosis. On rereview, we recorded the percentage of cells with nuclear p57 staining in villous cytotrophoblast and stromal cells. Ki-67 proliferative index (%) was determined by manual count of at least 500 villous cytotrophoblastic cells in areas with highest Ki-67 reactivity. Any intensity of nuclear staining was considered positive. The utility of p57 IHC is mainly to exclude or confirm CM. Although there is a significantly higher Ki-67 expression in CMs in comparison to PMs and NMAs, this did not add diagnostic utility. PMs tend to have higher Ki-67 expression than NMAs; however, the difference is not statistically significant. Our data suggest that the use of p57 and Ki-67 IHC cannot reliably distinguish PM from NMAs.

MeSH terms

  • Cyclin-Dependent Kinase Inhibitor p57 / metabolism
  • Female
  • Genotyping Techniques
  • Humans
  • Hydatidiform Mole / diagnosis*
  • Hydatidiform Mole / genetics
  • Hydatidiform Mole / pathology
  • Immunohistochemistry
  • Ki-67 Antigen / metabolism*
  • Placenta Diseases / diagnosis*
  • Placenta Diseases / genetics
  • Placenta Diseases / pathology
  • Pregnancy
  • Uterine Neoplasms / diagnosis*
  • Uterine Neoplasms / genetics
  • Uterine Neoplasms / pathology

Substances

  • Cyclin-Dependent Kinase Inhibitor p57
  • Ki-67 Antigen